Childhood uveitis not associated with juvenile idiopathic arthritis: a national survey of incidence, management and visual outcomes

被引:3
|
作者
Koay, Su-Yin [1 ]
Johnson, Megan [2 ]
Xing, Wen [1 ,3 ]
Foot, Barny [4 ]
MacEwen, Caroline [2 ]
Dahlmann-Noor, Annegret [1 ,3 ]
Thomas, Dhanes [1 ]
机构
[1] Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England
[2] Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
[3] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England
[4] Royal Coll Ophthalmologists, 18 Stephenson Way,Kings Cross, London NW1 2HD, England
关键词
ADALIMUMAB; COMPLICATIONS; METHOTREXATE; EPIDEMIOLOGY; EFFICACY; DISEASE;
D O I
10.1038/s41433-020-01267-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims To estimate the incidence of childhood uveitis not associated with juvenile idiopathic arthritis (JIA) in the United Kingdom. Methods Children under 16 years who presented with a new diagnosis of uveitis from November 2014 to October 2015 were identified prospectively through the British and Scottish Ophthalmological Surveillance Unit reporting card system. Incident questionnaires were sent to reporting ophthalmologists at presentation and 12 months. Results From 1st November 2014 to 31st October 2015, 119 cases were reported. Thirty-nine cases were excluded. The estimated minimum annual incidence of non-JIA uveitis in children younger than 16 years is 0.66 per 100,000 (95% CI 0.52-0.82). Median age at presentation was 10 years. 73% had bilateral uveitis. Median (IQR) BCVA in the worse eye was 0.3 (IQR 0.1-0.66) logMAR. The location of uveitis was: anterior 36%, intermediate 24%, posterior 6.8% and panuveitis 30%. 70% of cases were idiopathic. Most children were started on topical corticosteroids at presentation (86%, n = 51). At presentation, 31% (n = 19) were on started on systemic corticosteroids. At 1 year only 13% (n = 7) remained on corticosteroids, with the majority transitioned to steroid-sparing agents: methotrexate (30.8%, n = 16), mycophenolate (5.8%) and anti-TNF agents 5 (9.6%). At 1 year, 46% had ongoing intraocular inflammation despite treatment. The most common ocular adverse event was raised intraocular pressure (13.5%, n = 7). Conclusion Our study provides the first national population-based data of non-JIA childhood uveitis. Most children remain on treatment at 1 year, but visual acuity improves and none were eligible for sight-impairment registration.
引用
收藏
页码:2573 / 2578
页数:6
相关论文
共 50 条
  • [31] Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis
    Dana, MR
    MerayoLloves, J
    Schaumberg, DA
    Foster, CS
    OPHTHALMOLOGY, 1997, 104 (02) : 236 - 244
  • [32] Long-term outcomes in Juvenile idiopathic arthritis-associated uveitis
    Syeda, Sarah
    Nakhoul, Nakhoul
    Kubaisi, Buraa
    Foster, C. Stephen
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [33] Recommendations for the management of childhood juvenile idiopathic arthritis-type chronic anterior uveitis
    Smith, Justine R.
    Matthews, Janet M.
    Conrad, Diana
    Hall, Anthony J.
    Niederer, Rachael L.
    Singh-Grewal, Davinder
    Tay-Kearney, Mei-Ling
    Wells, Jane M.
    Zagora, Sophia L.
    McCluskey, Peter J.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 49 (01): : 38 - 45
  • [34] Specialty Practice and Cost Considerations in the Management of Uveitis Associated With Juvenile Idiopathic Arthritis
    Palestine, Alan G.
    Singh, Jasleen K.
    Kolfenbach, Jason R.
    Ozzello, Daniel J.
    JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS, 2016, 53 (04) : 246 - 251
  • [35] Prevention and Management of Cataracts in Children with Juvenile Idiopathic Arthritis-Associated Uveitis
    Angeles-Han, Sheila
    Yeh, Steven
    CURRENT RHEUMATOLOGY REPORTS, 2012, 14 (02) : 142 - 149
  • [36] Therapeutic advances in juvenile idiopathic arthritis - associated uveitis
    Gueudry, Julie
    Touhami, Sara
    Quartier, Pierre
    Bodaghi, Bahram
    CURRENT OPINION IN OPHTHALMOLOGY, 2019, 30 (03) : 179 - 186
  • [37] Development of Macular Edema and Impact on Visual Acuity in Uveitis Associated with Juvenile Idiopathic Arthritis
    de Boer, Joke
    Steijaert, Arjen
    van den Bor, Rutger
    Stellato, Rebecca
    Ossewaarde-van Norel, Jeannette
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2015, 23 (01) : 67 - 73
  • [38] Risk of Hypotony in Juvenile Idiopathic Arthritis Associated Uveitis
    Moradi, Ahmadreza
    Stroh, Inna G.
    Reddy, Ashvini K.
    Hornbeak, Dana M.
    Leung, Theresa G.
    Burkholder, Bryn M.
    Thorne, Jennifer E.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 169 : 113 - 124
  • [39] Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis
    Marino, Achille
    Marelli, Luca
    Nucci, Paolo
    Caporali, Roberto
    Miserocchi, Elisabetta
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (10) : 1997 - 2000
  • [40] Adalimumab for juvenile idiopathic arthritis-associated uveitis
    Magli, Adriano
    Forte, Raimondo
    Navarro, Pasqualina
    Russo, Giustina
    Orlando, Francesca
    Latanza, Loredana
    Alessio, Maria
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (06) : 1601 - 1606